CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis? Impact of Positive and Negative Lesion Site Remodeling on Clinical Outcomes : Insights From PROSPECT Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial

Original Research2020 May 5;141(18):1463-1476.

JOURNAL:Circulation. Article Link

Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure

JA Chirinos, L Zhao, Y Jia et al. Keywords: apolipoproteins M; heart failure; lipoproteins, HDL; sphingosine-1-phosphate; survival.

Full Text PDF